Multiple Sclerosis Trial, Recruiting (NCT06501950)

Multiple Sclerosis Trial, Recruiting NCT06501950 Sponsor: Heinrich-Heine University, Duesseldorf Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06501950 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with either relapsing-remitting MS (RRMS) or primary progressive MS (PPMS), based on the 2017 McDonald diagnostic guidelines
People who are currently being treated with a monoclonal antibody medication for MS, such as Natalizumab, Ofatumumab, or Ocrelizumab, taken as directed
People whose MS-related disability score (a standard scale used by doctors to measure MS severity) is 7.0 or below (confirm with trial site)

Who may not be able to join:

People who are currently experiencing an MS relapse, or who have received intravenous steroid treatment in the past six weeks
People who have another health condition — such as a psychiatric condition or dementia — that may make it difficult to understand or complete the study (the trial doctor will assess this on a case-by-case basis)
People who are taking additional immune-suppressing medications beyond the monoclonal antibody treatments listed above
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marc Günter Pawlitzki, PD Dr. med., Heinrich-Heine University, Duesseldorf

Phone: +49 02118117887

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06501950

Sponsor: Heinrich-Heine University, Duesseldorf

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +49 02118117887

More information: https://clinicaltrials.gov/study/NCT06501950

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with either relapsing-remitting MS (RRMS) or primary progressive MS (PPMS), based on the 2017 McDonald diagnostic guidelines
People who are currently being treated with a monoclonal antibody medication for MS, such as Natalizumab, Ofatumumab, or Ocrelizumab, taken as directed
People whose MS-related disability score (a standard scale used by doctors to measure MS severity) is 7.0 or below (confirm with trial site)

Who may not be able to join:

People who are currently experiencing an MS relapse, or who have received intravenous steroid treatment in the past six weeks
People who have another health condition — such as a psychiatric condition or dementia — that may make it difficult to understand or complete the study (the trial doctor will assess this on a case-by-case basis)
People who are taking additional immune-suppressing medications beyond the monoclonal antibody treatments listed above
People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Heinrich-Heine University, Duesseldorf

Registry

ClinicalTrials.gov

Start date

20 June 2024

Est. completion

1 October 2027

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Percentage of Progression independent from relapse (PIRA )at month 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov